You are here

Positive Phase III Results for Peginterferon in Multiple Sclerosis

Regulatory submission expected this year (Jan. 24)

In a pivotal phase III trial, peginterferon beta-1a (Biogen Idec) has shown promise as a potential treatment dosed every 2 or 4 weeks for relapsing-remitting multiple sclerosis (RRMS). Peginterferon beta-1a is a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and to prolong its exposure in the body, allowing a less frequent dosing schedule. Pegylation is the process of covalent attachment of polyethylene glycol (PEG) polymer chains to another molecule, normally a drug or a therapeutic protein.

The phase III ADVANCE trial was designed to evaluate the efficacy, safety, and tolerability of peginterferon beta-1a 125 mcg compared with placebo in more than 1,500 patients with RRMS. The study’s primary endpoint — the annualized relapse rate (ARR) at 1 year — was met for both the 2-week and 4-week dose regimens. Peginterferon beta-1a also met the secondary endpoints of the risk of 12-week confirmed disability progression, the proportion of patients who relapsed, and magnetic resonance imaging (MRI) assessments for both regimens.

At 1 year, the ARR reduction with the 2-week dosing regimen was 35.6% (P

Peginterferon beta-1a also met all of the trial’s secondary endpoints compared with placebo for both dosing regimens:

  • Peginterferon beta-1a reduced the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS), by 38% in both dosing arms (P
  • Peginterferon beta-1a reduced the proportion of patients who relapsed by 39% in the 2-week dosing arm (P P
  • Peginterferon beta-1a reduced the number of new or newly enlarging T2-hyperintense lesions on brain MRI scans by 67% in the 2-week dosing arm (P P

Regulatory submission in the U.S. is expected this year.

Source: Biogen Idec; January 24, 2013.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Attacks Cancerous Cells, Leaves Healthy Tissues Alone